Pharmacological Challenges in Neurocritical Care

No abstract is available for this paper.

• Publication year

  2020

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-3-030-36548-6_6
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Pain management in neurocritical care; an update

  2018cited by this paper
• Enoxaparin Dosing at Extremes of Weight: Literature Review and Dosing Recommendations

  2018cited by this paper
• Drug dosing in obese adults.

  2017cited by this paper
• Direct oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced age

  2017cited by this paper
• Medicating patients during extracorporeal membrane oxygenation: the evidence is building

  2017cited by this paper
• Comprehensive Guidance for Antibiotic Dosing in Obese Adults

  2017cited by this paper
• Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society

  2016cited by this paper
• Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy.

  2016cited by this paper
• Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH

  2016cited by this paper
• Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient

  2016cited by this paper
• Prospective, Controlled Study of Acyclovir Pharmacokinetics in Obese Patients

  2016cited by this paper
• Dosing of antifungal agents in obese people

  2016cited by this paper
• Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage

  2016cited by this paper
• Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study

  2015cited by this paper
• Drug prescribing in renal failure

  2015cited by this paper
• A review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough?

  2015cited by this paper
• Pharmacokinetics of Vancomycin in Extremely Obese Patients with Suspected or Confirmed Staphylococcus aureus Infections

  2015cited by this paper
• Levetiracetam Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemofiltration and Venoarterial Extracorporeal Membrane Oxygenation

  2015cited by this paper
• Obesity and Antiplatelets-Does One Size Fit All?

  2015cited by this paper
• Designing drug regimens for special intensive care unit populations.

  2015cited by this paper
• Perioperative Pharmacologic Management of Patients with End Stage Renal Disease

  2015cited by this paper
• Individualized Vancomycin Dosing in Obese Patients: A Two‐Sample Measurement Approach Improves Target Attainment

  2015cited by this paper
• THE EFFECT OF OBESITY ON DOSE OF DEXMEDETOMIDINE WHEN ADMINISTERED WITH FENTANYL DURING POSTOPERATIVE MECHANICAL VENTILATION--RETROSPECTIVE.

  2015cited by this paper
• Ketamine infusion for patients receiving extracorporeal membrane oxygenation support: a case series

  2015cited by this paper
• Propofol, midazolam, vancomycin and cyclosporine therapeutic drug monitoring in extracorporeal membrane oxygenation circuits primed with whole human blood

  2015cited by this paper
• Vancomycin population pharmacokinetics during extracorporeal membrane oxygenation therapy: a matched cohort study

  2014cited by this paper
• The Dosing and Monitoring of Argatroban for Heparin-Induced Thrombocytopenia during Extracorporeal Membrane Oxygenation: A Word of Caution

  2014cited by this paper
• Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis

  2014cited by this paper
• Sedation Practice in Veno-Venous Extracorporeal Membrane Oxygenation: An International Survey

  2013cited by this paper
• Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects.

  2013cited by this paper
• Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease

  2013cited by this paper
• In vitro clearance of dexmedetomidine in extracorporeal membrane oxygenation

  2013cited by this paper
• Antimicrobial dosing in acute renal replacement.

  2013cited by this paper
• Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit

  2013cited by this paper
• Guidelines for the Evaluation and Management of Status Epilepticus

  2012cited by this paper
• Lacosamide

  2012cited by this paper
• Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation

  2012cited by this paper
• Association of estimated GFR with platelet inhibition in patients treated with clopidogrel.

  2012cited by this paper
• Impact of Obesity on Drug Metabolism and Elimination in Adults and Children

  2012cited by this paper
• Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation.

  2012cited by this paper
• Dexmedetomidine Controls Agitation and Facilitates Reliable, Serial Neurological Examinations in a Non-Intubated Patient with Traumatic Brain Injury

  2011cited by this paper
• Effect of Obesity on the Pharmacokinetics of Drugs in Humans

  2010cited by this paper
• Estimating the glomerular filtration rate in obese adult patients for drug dosing.

  2010cited by this paper
• Dose adjustment of anaesthetics in the morbidly obese.

  2010cited by this paper
• Pharmacokinetic Characteristics of Bolus‐Administered Mannitol in Patients Undergoing Elective Craniotomy

  2010cited by this paper
• Pharmacokinetics and drug dosing in obese children.

  2010cited by this paper
• Should Dosing of Rocuronium in Obese Patients Be Based on Ideal or Corrected Body Weight?

  2009cited by this paper
• Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention.

  2009cited by this paper
• Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis

  2009cited by this paper
• The Early and Delayed Analgesic Effects of Ketamine After Total Hip Arthroplasty: A Prospective, Randomized, Controlled, Double-Blind Study

  2009cited by this paper
• The Impact of Continuous Renal Replacement Therapy on Drug Therapy

  2009cited by this paper
• Predictors of mortality in patients with suspected propofol infusion syndrome

  2008cited by this paper
• Comprar Introduction to Renal Therapeutics | Caroline Ashley | 9780853696889 | Pharmaceutical Press

  2008cited by this paper
• Neuromuscular effects of cisatracurium in morbidly obese patients.

  2008cited by this paper
• Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment

  2007cited by this paper
• In vitro drug adsorption and plasma free hemoglobin levels associated with hollow fiber oxygenators in the extracorporeal life support (ECLS) circuit.

  2007cited by this paper
• Drug Removal by Plasmapheresis: An Evidence‐Based Review

  2007cited by this paper
• Dosing in Obesity: A Simple Solution to a Big Problem

  2007cited by this paper
• Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention.

  2007cited by this paper
• Pharmacokinetic changes in critical illness.

  2006cited by this paper
• Voriconazole Therapeutic Drug Monitoring

  2006cited by this paper
• The Dose of Succinylcholine in Morbid Obesity

  2006cited by this paper
• Sedative clearance during extracorporeal membrane oxygenation

  2005cited by this paper
• Pharmacokinetic mass of fentanyl for postoperative analgesia in lean and obese patients.

  2005cited by this paper
• DrugBank: a comprehensive resource for in silico drug discovery and exploration

  2005cited by this paper
• Clinical Pharmacokinetics of Levetiracetam

  2004cited by this paper
• Practice guidelines for the management of bacterial meningitis.

  2004cited by this paper
• The Effects of Cisatracurium on Morbidly Obese Women

  2004cited by this paper
• Opioids in renal failure and dialysis patients.

  2004cited by this paper
• The Pharmacodynamic Effects of Rocuronium When Dosed According to Real Body Weight or Ideal Body Weight in Morbidly Obese Patients

  2004cited by this paper
• Kinetics of ceftazidime during plasmapheresis

  2004cited by this paper
• Laudanosine, an atracurium and cisatracurium metabolite.

  2002cited by this paper
• Pathophysiology of bacterial meningitis: mechanism(s) of neuronal injury.

  2002cited by this paper
• Vancomycin Removal during a Plasma Exchange Transfusion

  2001cited by this paper
• In vitro evaluation of sedative drug losses during extracorporeal membrane oxygenation

  2000cited by this paper
• Phenobarbital Dosing and Pharmacokinetics in a Neonate Receiving Extracorporeal Membrane Oxygenation

  1999cited by this paper
• Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes.

  1999cited by this paper
• Pharmacokinetics of rocuronium bromide in obese female patients.

  1999cited by this paper
• Methadone is poorly removed by haemodialysis.

  1999cited by this paper
• Vancomycin dosing in morbidly obese patients

  1998cited by this paper
• Treatment of refractory intracranial hypertension with 23.4% saline.

  1998cited by this paper
• Clobazam in partial status epilepticus.

  1998cited by this paper
• A Primer on Continuous Renal Replacement Therapy for Critically Ill Patients

  1998cited by this paper
• Steady-state serum concentrations of carbamazepine and valproic acid in obese and lean patients with epilepsy.

  1998cited by this paper
• Hepatic Drug Metabolism in Critical Illness

  1998cited by this paper
• Vancomycin removal by plasmapheresis.

  1997cited by this paper
• Effect of Acute Phase Response on Phenytoin Metabolism in Neurotrauma Patients

  1997cited by this paper
• Gastrointestinal permeability and absorptive capacity in sepsis.

  1996cited by this paper
• Importance of the Organ-Independent Elimination of Cisatracurium

  1996cited by this paper
• Vancomycin Removal by Plasmapheresis

  1996cited by this paper
• Expanded gentamicin volume of distribution in critically ill adult patients receiving total parenteral nutrition

  1995cited by this paper
• Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique

  1993cited by this paper
• Influence of therapeutic plasmapheresis on elimination of ceftiaxone

  1993cited by this paper
• Pharmacokinetics and Pharmacodynamics of Vecuronium in the Obese Surgical Patient

  1992cited by this paper
• Phenobarbital Pharmacokinetics in Obesity

  1992cited by this paper
• Phenytoin pharmacokinetics in critically ill trauma patients

  1988cited by this paper
• High-dose barbiturate control of elevated intracranial pressure in patients with severe head injury.

  1988cited by this paper
• Pentobarbital Pharmacokinetics in Patients with Severe Head Injury

  1987cited by this paper
• Atracurium, vecuronium and pancuronium in end-stage renal failure. Dose-response properties and interactions with azathioprine.

  1987cited by this paper
• Effect of plasma exchange on phenytoin plasma concentration.

  1986cited by this paper

• No citing papers are available for this paper.